Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Henry M. Jackson Foundation for the Advancement of Military Medicine · with Centers for Disease Control and Prevention, Food and Drug Administration (FDA) · NCT07287137

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–79 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
54
US sites recruiting
1
Study start
November 12, 2025
Record last updated
October 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Being studied: Pfizer-BioNTech mRNA COVID-19 vaccine; Novavax recombinant protein vaccine

Conditions: COVID -19; COVID - 19; COVID 19; Influenza; Respiratory Virus; Respiratory Viruses; Respiratory Virus Infection; Respiratory Virus Infections

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18-79 years old
  • Have a history of any of the following risk factors for severe COVID:

Current

  • Age > 65 years old
  • Physical inactivity (defined as \<150 mins of moderate activity per week or \<75 mins of vigorous activity per week)
  • HIV with CD4 count ≥ 500 cells/ul
  • Smoker
  • Obesity with BMI ≥ 30 and \< 40

History of

  • Asthma
  • Depression or other mood disorder
  • Schizophrenia spectrum disorder
  • Cerebrovascular disease
  • Heart failure
  • Coronary artery disease
  • Cardiomyopathy
  • Pulmonary embolism
  • Pulmonary hypertension
  • Cystic fibrosis
  • Bronchiectasis
  • Chronic obstructive pulmonary disease
  • Interstitial Lung Disease
  • Stage I or II chronic kidney disease (Stage 1 defined as normal GFR (> 90) but with other signs of kidney damage such as proteinuria or hematuria) (Stage 2 defined as having a glomerular filtration rate (GFR) of 60 - 89 ml/min/1.73m2)
  • Gestational diabetes
  • Type 1 diabetes with most recent HgbA1C \< 7.5%
  • Type 2 diabetes with most recent HgbA1C \< 7.5%
  • Liver disease without cirrhosis and with liver enzyme levels (AST and ALT) no greater than three times the upper limit of normal
  • Smoking
  • Military Health System beneficiary and DEERS eligible
  • Willing to be randomized to receive either the Novavax COVID-19 vaccine or the mRNA Pfizer-BioNTech COVID-19 vaccine
  • Will be able to return for a clinic visit in approximately 30 days, Day 150, and be able to follow-up online for the next 9 months.

Exclusion Criteria

  • History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
  • Received a COVID-19 vaccine in the last 3 months.
  • Tested positive for COVID-19 in the past 3 months.
  • Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit.
  • Active use of immune modulating medications.
  • Defined as active use of chronic immune modulating medications such as systemic corticosteroids at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function.
  • Diagnosed with immunocompromised stated.
  • Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen).
  • Diabetes with the most recent HgbA1C ≥ 7.5.
  • Stage III or greater chronic kidney disease
  • Defined as estimated glomerular filtration rate \< 60 ml/min/1.73m2)
  • Obesity with a BMI ≥ 40
  • HIV with a CD4 cell count \< 500 cells/ul
  • History of solid organ or bone marrow transplant.
  • Active malignancy
  • Defined as any cancer that is currently being treated or has shown evidence of progression within the past year.
  • Chronic liver disease with compensated or decompensated cirrhosis, or liver enzyme levels (AST or ALT) greater than three times the upper limit of normal.

Recruiting US locations

  • Walter Reed National Military Medical Center

    Bethesda, MD 20814

    Site contact: Irma Barahona · 301-319-8673 · irma.l.barahona.ctr@health.mil

Study contacts (from the official record)

  • Marianne Spevak, BSHS · 240-694-2067 · mspevak@hjf.org
All vaccine studies in Maryland →
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study (NCT07287137) | Bored Studies